Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Weight Loss AND Overweight

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Weight Loss AND Overweight. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-001049-24 Sponsor Protocol Number: NN8022-1839 Start Date*: 2008-12-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-002199-88 Sponsor Protocol Number: NN8022-1922 Start Date*: 2008-12-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-002470-86 Sponsor Protocol Number: 20190218 Start Date*: 2023-05-08
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without...
    Medical condition: Overweight and Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002868-14 Sponsor Protocol Number: CLIK066B2201 Start Date*: 2017-04-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 wee...
    Medical condition: change in weight in obese or overweight adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003395-22 Sponsor Protocol Number: W3600586 Start Date*: 2008-09-04
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition
    Medical condition: Weight Loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002145-15 Sponsor Protocol Number: NOK0023 Start Date*: 2023-10-31
    Sponsor Name:Nederlandse Obesitas Kliniek
    Full Title: Applying Mysimba in patients with weight regain after bariatric surgery
    Medical condition: Weight regain post bariatric surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000677-77 Sponsor Protocol Number: S61338 Start Date*: 2018-06-26
    Sponsor Name:University Hospital Leuven
    Full Title: Novel strategies in weight loss in women with polycystic ovary syndrome: does the gut microbiome play a role?
    Medical condition: overweight and obese women with polycystic ovary syndrome (PCOS) at risk for metabolic syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000220-19 Sponsor Protocol Number: 2.2 Start Date*: 2020-09-24
    Sponsor Name:Verein zur Förderung von Wissenschaft und Forschung an der 1. Med. Abteilung der Krankenanstalt Rudolfstiftung
    Full Title: Comparing effects of weight loss by Liraglutide 3.0 mg with conventional liver fasting in non-alcoholic fatty liver disease before bariatric surgery
    Medical condition: Obesity and NAFLD can increase the risk and complexity of bariatric surgery up to 20%. Reducing the weight and liver size before bariatric surgery improves the operation area and reduces complicati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005121-24 Sponsor Protocol Number: NN9838-4609 Start Date*: 2022-07-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants withoverweight or obesityand type 2 diabetes
    Medical condition: Overweight, Obesity and Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005619-33 Sponsor Protocol Number: NN8022-4272 Start Date*: 2016-12-14
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004866-15 Sponsor Protocol Number: EMI111963 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A Longitudinal MRI Study of Changes in Regional Body Composition During Orlistat (60mg)-Assisted Dieting
    Medical condition: Weight loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047900 Weight loss LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002479-37 Sponsor Protocol Number: 1404-0036 Start Date*: 2021-03-15
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Prematurely Ended) NL (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001692-30 Sponsor Protocol Number: 003/07 Start Date*: 2009-11-06
    Sponsor Name:Certmedica International GmbH
    Full Title: monocentric randomised double-blind pilot trial, double dummy design for comparison of two therapy reginem formoline L112 vs. Orlistat 60 mg in patients with overweight or adipositas
    Medical condition: The product alli and the comparsion product fromoline L112 (medical device) decrease weight by influencing the fat absorption. The effects of both regimes should cause similar results in weight loss.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005163-16 Sponsor Protocol Number: U1111-1171-4970 Start Date*: 2016-05-30
    Sponsor Name:The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark
    Full Title: Effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis. A randomised, double blind, placebo-controlled, parallel group, single-centre trial
    Medical condition: Adult (≥ 18 years of age) overweight or obese patients (BMI ≥ 27 kg/m2 ) above 18 years of age with knee osteoarthritis (OA) defined by clinical diagnosis of knee OA according to the American Colle...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10023476 Knee osteoarthritis LLT
    19.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003293-93 Sponsor Protocol Number: 14072011 Start Date*: 2011-09-23
    Sponsor Name:Sint Antonius Ziekenhuis
    Full Title: Cyp3A4 metabolism before and after surgery induced weight loss in morbidly obese patients, using midazolam as a model drug
    Medical condition: Morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004064-35 Sponsor Protocol Number: Start Date*: 2018-04-17
    Sponsor Name:Southern Health NHS Foundation Trust
    Full Title: Liraglutide and the management of overweight and obesity in people with schizophrenia: a pilot study
    Medical condition: Schizophrenia, schizoaffective disorder or first episode psychosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-002492-14 Sponsor Protocol Number: EFC10139 Start Date*: 2008-03-28
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial tr...
    Medical condition: Patients with BMI > or = 30 kg/m2 or BMI > 27 kg/m2 with associated risk factors such as Type 2 Diabetes mellitus or Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    10.1 10045260 LLT
    10.1 10058108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-000043-31 Sponsor Protocol Number: 383 Start Date*: 2020-03-26
    Sponsor Name:Groupe Hospitalier Paris Saint-Joseph
    Full Title: Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients
    Medical condition: obese type 2 diabetic hemodialysis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002805-88 Sponsor Protocol Number: J2A-MC-GZGI Start Date*: 2021-09-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities
    Medical condition: Obesity and Overweight with Weight-Related Comorbidities
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-001003-38 Sponsor Protocol Number: RGHT000540 Start Date*: 2008-08-01
    Sponsor Name:The Royal Group of Hospitals, Belfast Trust
    Full Title: A study investigating rimonabant versus placebo in conjunction with a strict low-fat weight reduction diet in overweight and obese subjects: effects on glucose and lipid metabolism and cardiovascul...
    Medical condition: This study will investigate subjects who are overweight and obese with Body Mass Index >27kg/m2.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:32:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA